Here is a report from the PBT1 trial where one patient suffered vision problems, possibly attributed to PBT1(CQ) and the condition resolved when the treatment was stopped.
[One patient in the treatment group developed impaired visual acuity and color vision during weeks 31 to 36 while she was receiving clioquinol, 375 mg twice daily. Her symptoms resolved on treatment cessation. A 2012 update of this review included trials through December 2011. Only the Lannfelt et al trial discussed below was identified. (17)
Further studies of PBT1 have been abandoned in favor of a successor compound, PBT2.]
Here it looks like the vision effects are reversible . That was CQ
Here is a report from the PBT1 trial where one patient suffered...
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(16.7%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $2.563K | 733.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 41 | 49380730 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 126748541 | 18 |
View Market Depth
| Last trade - 11.57am 12/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |